Patents by Inventor Robert A. Mook

Robert A. Mook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250228854
    Abstract: The present disclosure relates to a class of pyrimidopyran compounds substituted with piperazine bridge and their applications thereof, such as compounds of Formulae (I?), (I?), or (I), stereoisomers thereof, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 31, 2025
    Publication date: July 17, 2025
    Inventors: Zhijian CHEN, Jing ZHANG, Robert A. MOOK, JR., Tienan WANG, Haibo XIE, Jiuxiang ZHU
  • Patent number: 11987579
    Abstract: Described are niclosamide analogue compounds, pharmaceutical compositions thereof, and method of using the corner pounds and compositions for treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway, such as cancer, fatty liver, antibiotic resistance, and viral infection. The disclosed compounds and compositions may also be used for modulating mitochondrial function and for treating certain non-cancer diseases and/or diorders, such as diabetes, fibrotic disease, primary sclerosing cholangitis.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 21, 2024
    Assignee: Duke University
    Inventors: Robert A. Mook, Wei Chen, Jiangbo Wang, Xiu-Rong Ren, Herbert Kim Lyerly
  • Publication number: 20210179615
    Abstract: Described are niclosamide analogue compounds, pharmaceutical compositions thereof, and method of using the corner pounds and compositions for treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway, such as cancer, fatty liver, antibiotic resistance, and viral infection. The disclosed compounds and compositions may also be used for modulating mitochondrial function and for treating certain non-cancer diseases and/or diorders, such as diabetes, fibrotic disease, primary sclerosing cholangitis.
    Type: Application
    Filed: July 30, 2019
    Publication date: June 17, 2021
    Inventors: Robert A. Mook, Wei Chen, Jiangbo Wang, Xiu-Rong Ren, Herbert Kim Lyerly
  • Patent number: 10905665
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 2, 2021
    Assignee: Duke University
    Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
  • Patent number: 10562864
    Abstract: Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 18, 2020
    Assignee: Duke University
    Inventors: Wei Chen, Herbert Kim Lyerly, Xiu-rong Ren, Jiangbo Wang, Hongtao Guo, Amy Hobeika, Robert A. Mook, Jr.
  • Publication number: 20200038350
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Application
    Filed: June 24, 2016
    Publication date: February 6, 2020
    Inventors: Wei Chen, Robert A. Mook, JR., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
  • Publication number: 20190083638
    Abstract: Disclosed herein are conjugates of a therapeutic compound and polypeptides, such as a conjugate of niclosamide and an elastin-like polypeptide. These conjugates may form nanoparticles through self-assembly, which improve the solubility, bioavailability, and pharmacokinetic profiles of the therapeutic compound. Also disclosed are methods for treating cancer, parasite infection, bacterial infection, viral infection, metabolic diseases, Type II diabetes, NASH, NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis.
    Type: Application
    Filed: July 25, 2018
    Publication date: March 21, 2019
    Inventors: Wei Chen, Jayanta Bhattacharyya, Xiu-Rong Ren, Robert A. Mook, Jiangbo Wang, Ivan Spasojevic, Richard Premont, Xinghai Li, Ashutosh Chilkoti
  • Publication number: 20190077772
    Abstract: Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
    Type: Application
    Filed: November 14, 2018
    Publication date: March 14, 2019
    Inventors: Wei Chen, Herbert Kim Lyerly, Xiu-rong Ren, Jiangbo Wang, Hongtao Guo, Amy Hobeika, Robert A. Mook
  • Publication number: 20190070154
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial Sand viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Application
    Filed: June 24, 2016
    Publication date: March 7, 2019
    Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly
  • Patent number: 10189797
    Abstract: Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: January 29, 2019
    Assignee: Duke University
    Inventors: Wei Chen, Herbert Kim Lyerly, Xiu-rong Ren, Jiangbo Wang, Hongtao Guo, Amy Hobeika, Robert A. Mook
  • Publication number: 20170190675
    Abstract: Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
    Type: Application
    Filed: December 30, 2016
    Publication date: July 6, 2017
    Inventors: Wei Chen, Herbert Kim Lyerly, Xiu-rong Ren, Jiangbo Wang, Hongtao Guo, Amy Hobeika, Robert A. Mook
  • Patent number: 9512106
    Abstract: Compounds of general Formulas (I), (IA), (IB) are described, along with compositions containing the same and methods of use thereof, inhibiting the hedgehog pathway in a cell or inhibiting unwanted proliferation of a cell.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: December 6, 2016
    Assignee: Duke University
    Inventors: Wei Chen, Jiangbo Wang, Robert A. Mook, Jr., Lawrence S. Barak, H. Kim Lyerly, Anthony Angelo Ribeiro
  • Publication number: 20150166509
    Abstract: Compounds of general Formulas (I), (IA), (IB) are described, along with compositions containing the same and methods of use thereof, inhibiting the hedgehog pathway in a cell or inhibiting unwanted proliferation of a cell.
    Type: Application
    Filed: September 16, 2013
    Publication date: June 18, 2015
    Inventors: Wei Chen, Jiangbo Wang, Robert A. Mook, JR., Lawrence S. Barak, H. Kim Lyerly, Anthony Angelo Ribeiro
  • Patent number: 6911455
    Abstract: The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipients for use in the formulations of the invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: June 28, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Alison G. Floyd, Mir A Hashim, Peiyuan Lin, Robert A. Mook, Andrea Sefler, Kathleen Cornell Meserve, Patricia Neal Ricciarelli, Timothy David Spitzer
  • Publication number: 20030096839
    Abstract: The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipient for use in the formulations of invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.
    Type: Application
    Filed: June 13, 2002
    Publication date: May 22, 2003
    Inventors: Alison G. Floyd, Mir A. Hashim, Pelyuan Lin, Robert A. Mook, Andrea Sefler, Kathleen Cornell Meserve, Patricia Neal Ricciarelli, Timothy David Spitzer
  • Patent number: 5846976
    Abstract: The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: December 8, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth William Batchelor, Stephen Vernon Frye, George F. Dorsey, Jr., Robert A. Mook, Jr.
  • Patent number: 5705693
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted arginine, lysine or ornithine residues, or derivatives thereof, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: January 6, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Randolph B. DePrince, Kevin L. Facchine, George S. Lewis, Jason G. Lewis, Kuei-Ying Lin, Mark D. Matteucci, Robert A. Mook, Jr., Richard W. Wagner
  • Patent number: 5565467
    Abstract: The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: October 15, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth W. Batchelor, Stephen V. Frye, George F. Dorsey, Jr., Robert A. Mook, Jr.
  • Patent number: 5241069
    Abstract: This invention relates to the new process for preparing the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent and intermediates of the formula (Vlb) use in that process ##STR1## wherein X is chloro, bromo or iodo and R is (C.sub.1-6) alkyl.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: August 31, 1993
    Assignees: Glaxo Inc., Univeristy of Minnesoota
    Inventors: Robert Vince, Mark L. Peterson, John W. Lackey, Robert A. Mook, Jr., John J. Partridge
  • Patent number: 5126452
    Abstract: This invention relates to new process for preparing certain optically active purine substituted cyclopentene derivatives and novel intermediates used in this process. In particular, the invention concerns the synthesis of the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent, and certain intermediates.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: June 30, 1992
    Assignee: Glaxo Inc.
    Inventors: Robert Vince, Mark L. Peterson, John W. Lackey, Robert A. Mook, Jr., John J. Partridge